Skip to main content

Table 1 Baseline demographics of participating patients

From: The human anti-IL-1β monoclonal antibody ACZ885 is effective in joint inflammation models in mice and in a proof-of-concept study in patients with rheumatoid arthritis

Characteristic ACZ885
  0.3 mg/kg (n = 6) 1.0 mg/kg (n = 6) 3.0 mg/kg (n = 6) mg/kg (n = 20) Placebo (n = 15)
Age (years; mean ± SD) 61 ± 7 53 ± 14 57 ± 7 50 ± 11 55 ± 10
hsCRP (mg/l; median [range]) 17.8 (1.6–95.3) 43.8 (5.8–89.3) 3.0 (2.0–43.4) 11.1 (1.5–28.4) 6.4 (0.2–66.2)
DAS28 (mean ± SD) 6.5 ± 0.8 6.6 ± 1.2 6.7 ± 1.5 6.2 ± 0.7 6.7 ± 0.6
Number of tender joints (mean ± SD) 17 ± 9.2 15 ± 6.2 22 ± 8.5 17 ± 7.3 20 ± 6.3
Number of swollen joints (mean ± SD) 13 ± 6.3 12 ± 4.3 12 ± 7.4 11 ± 4.8 12 ± 5.2
Methotrexate dose (n/mg median [range])a      
   Oral 6/17.5 (15–25) 5/15 (10–15) 4/15 (15–15) 13/15 (10–22.5) 5/15 (10–20)
   Parenteral 0 1/10 (10–10) 2/22.5 (20–25) 7/15 (10–22.5) 10/15 (10–25)
  1. aNumbers of patients receiving 15 mg/week were 2, 4, 4, 10 and 6 in the 0.3, 1, 3, 10 mg/kg and placebo cohorts, respectively. SD, standard deviation.